These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 14623020)

  • 1. Activation and suppression of the proinflammatory immune response by Vibrio cholerae toxins.
    Satchell KJ
    Microbes Infect; 2003 Nov; 5(13):1241-7. PubMed ID: 14623020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New evidence for an inflammatory component in diarrhea caused by selected new, live attenuated cholera vaccines and by El Tor and Q139 Vibrio cholerae.
    Silva TM; Schleupner MA; Tacket CO; Steiner TS; Kaper JB; Edelman R; Guerrant R
    Infect Immun; 1996 Jun; 64(6):2362-4. PubMed ID: 8675353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of oral cholera vaccines during pregnancy in developing countries.
    Khan AI; Islam MT; Qadri F
    Hum Vaccin Immunother; 2017 Oct; 13(10):2245-2246. PubMed ID: 28825876
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-O1 Vibrio cholerae and epidemic cholera.
    Commun Dis Rep CDR Wkly; 1993 Jun; 3(24):107. PubMed ID: 7693194
    [No Abstract]   [Full Text] [Related]  

  • 5. Promotion of colonization and virulence by cholera toxin is dependent on neutrophils.
    Queen J; Satchell KJ
    Infect Immun; 2013 Sep; 81(9):3338-45. PubMed ID: 23798539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM
    J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic manipulation of Vibrio cholerae for vaccine development: construction of live attenuated El Tor candidate vaccine strains.
    Benítez JA; Silva AJ; Rodríguez BL; Fando R; Campos J; Robert A; García H; García L; Pérez JL; Oliva R; Torres CA; Ledón T
    Arch Med Res; 1996; 27(3):275-83. PubMed ID: 8854382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contribution of accessory toxins of Vibrio cholerae O1 El Tor to the proinflammatory response in a murine pulmonary cholera model.
    Fullner KJ; Boucher JC; Hanes MA; Haines GK; Meehan BM; Walchle C; Sansonetti PJ; Mekalanos JJ
    J Exp Med; 2002 Jun; 195(11):1455-62. PubMed ID: 12045243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection and immunity to Vibrio cholerae, Salmonella typhimurium and Escherichia coli in a rabbit model.
    Guinée PA; Jansen WH; Rijpkema SG
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Nov; 270(1-2):260-9. PubMed ID: 2464884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of toll-like receptor 4 in the proinflammatory response to Vibrio cholerae O1 El tor strains deficient in production of cholera toxin and accessory toxins.
    Haines GK; Sayed BA; Rohrer MS; Olivier V; Satchell KJ
    Infect Immun; 2005 Sep; 73(9):6157-64. PubMed ID: 16113340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Process development for a Cuban cholera vaccine based on the attenuated strain Vibrio cholerae 638.
    Talavera A; Año G; García H; Moreira T; Delgado H; Riverón L; Gil S; Miranda A; Cedré B; Valmaseda T; Pino Y; Pérez JL; Infante JF; García L; Sierra G
    Vaccine; 2006 May; 24(18):3746-9. PubMed ID: 16085342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vibrio cholerae O1 vibriocidal and anti-cholera toxin antibodies in O139 Bengal cholera patients.
    Takeda T; Ramamurthy T; Chowdhury AS; Dutta D; Bhattacharya SK; Deb BC; Nair GB; Takeda Y
    J Infect; 1994 Sep; 29(2):233-5. PubMed ID: 7806891
    [No Abstract]   [Full Text] [Related]  

  • 14. Vibrio cholerae infection and acquired immunity in an adult rabbit model.
    Guinée PA; Jansen WH; Peters PW
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Feb; 259(1):118-31. PubMed ID: 4002931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The immunology of cholera and the molecular biology of cholera toxin. Recent progress and future perspectives].
    Carrada-Bravo T
    Rev Alerg Mex; 1994; 41(3):69-76. PubMed ID: 9377108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
    Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
    Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
    Stewart-Tull DE; Lucas C; Bleakley CR
    Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholera: Immunity and Prospects in Vaccine Development.
    Harris JB
    J Infect Dis; 2018 Oct; 218(suppl_3):S141-S146. PubMed ID: 30184117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmid-induced loss of virulence in Vibrio cholerae.
    Sinha VB; Srivastava BS
    Nature; 1978 Dec; 276(5689):708-9. PubMed ID: 732874
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunoglobulins in bile and serum of the rabbit associated with protection after Vibrio cholerae infection and vaccination.
    Rijpkema SG; Jansen WH; Gielen H; Guinée PA
    Microb Pathog; 1987 Nov; 3(5):365-75. PubMed ID: 2462153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.